The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Implementing precision medicine for biliary tract cancer
Shubham Pant, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the implementation of precision medicines for biliary tract cancer. Targeted therapies are approved for intrahepatic cholangiocarcinoma (CCA) targeting FGFR fusions and alterations which are significantly enriched in intrahepatic CCA, including pemigatinib and futibatinib, as well as ivosidenib for targeting IDH1. Additionally, agents are currently in development for HER2 overamplification, which is mostly seen in gallbladder cancer and extrahepatic cholangiocarcinoma. The scope of genomic aberrations o identified in biliary tract cancer highlights the importance of genomic testing in this patient population with next-generation sequencing (NGS) to take advantage of the targeted therapies available. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
